Please assess the completion status of the following clinical trial:

Trial Title: Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 20\~85~* Acute period (ischemic stroke confirmation on DWI or TIA within 14 days after symptom onset)~* Below 20 point of initial NIHSS score within 14 days after stroke onset and enrolment.~* Confirmation of atherosclerotic or steno-occlusive stroke mechanism (proximal cerebral arteries) on CTA or MRA .~* At least hemodynamically, perfusion status of a candidate is stage II or III (decrease of regional Cerebral blood flow on CBF map), moyamoya disease~* If female then not of childbearing potential~* Informed consent~Exclusion Criteria:~* Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH), arterio-venous malformation (AVM), cerebral aneurysm, or cerebral neoplasm~* Treated with a thrombolytic \<24 hours (if \>24 hours and excluded ICH then eligible)~* Score \>=1 on the NIHSS item 1a~* Pre-stroke mRS score \<2~* Uncontrolled hypertension(irregularity systollic BP \> 150mmHg~* Previous treatment with erythropoietin~* At screening: Hemoglobin \>14 g/dl, prolonged PT or PTT, serum Cr \>2.0 ,mg/dl, BUN \>40, thrombocytopenia or neutropenia as defined by the lower limit of normal for the platelet count or white blood cell count, respectively (absolute neutrophil count of \> 1800/mm3 required for participation), or \> 2 times of normal on liver function tests (SGOT, SGPT, total bilirubin)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
- Group B (Type: NO_INTERVENTION): mechanical barrier disruption procedure Drug: no-specific intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).